Literature DB >> 12747760

Characterization of cells prepared by dendritic cell-tumor cell fusion.

Eva Gottfried1, René Krieg, Christian Eichelberg, Reinhard Andreesen, Andreas Mackensen, Stefan W Krause.   

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells currently being discussed as a potent tool for antitumor vaccination strategies. The approach consisting of the in vitro generation of DC-tumor cell hybrids may be advantageous for individualized vaccines since there is no need for the determination of MHC-restricted tumor-associated antigens recognized by T cells. As recent vaccination studies gave varying results, we tested the impact of the fusion treatment on the cells used. Polyethylene glycol-induced fusion, as well as electrofusion, proved to be suitable for generating hybrid cells although at a low frequency. Of note, both methods also gave rise to DCs having phagocytosed apoptotic tumor cells. The expression of surface molecules relevant for specific T cell stimulation was not altered by the fusion procedure and the DCs were still functionally active as demonstrated by the secretion of IL-12 and the uptake of antigen. The cells were able to induce a tumor-specific T cell response in vitro and therefore deserve further investigation as potent tools for immunotherapy trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12747760

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  6 in total

Review 1.  Dendritic cells in melanoma immunotherapy.

Authors:  Mark B Faries; Brian J Czerniecki
Journal:  Curr Treat Options Oncol       Date:  2005-05

2.  Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells.

Authors:  Marko Usaj; Katja Trontelj; Damijan Miklavcic; Masa Kanduser
Journal:  J Membr Biol       Date:  2010-07-14       Impact factor: 1.843

Review 3.  Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2011-04-26

Review 4.  Regulation of tumor immunity by tumor/dendritic cell fusions.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Akitaka Takahara; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-10-26

5.  Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer.

Authors:  Jingxian Ding; Wei Jin; Canming Chen; Zhiming Shao; Jiong Wu
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

6.  Purified dendritic cell-tumor fusion hybrids supplemented with non-adherent dendritic cells fraction are superior activators of antitumor immunity.

Authors:  Yunfei Zhang; Wen Luo; Yucai Wang; Yunyan Liu; Lianhe Zheng
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.